MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-25-2026
Exicure Market Cap 2011-2026 | XCUR
As of April 07, 2026 Exicure has a market cap of $ 25.3 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Exicure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 M | 9.42 M | 3.77 M | 4.39 M | 588 K | 186 M | 218 M | 122 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 218 M | 588 K | 71.6 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.34 | -3.6 % | $ 357 M |  Britain |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 20.13 | -1.13 % | $ 2.81 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.57 | -3.57 % | $ 16.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Equillium
EQ
|
118 M | $ 2.04 | 1.24 % | $ 117 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Fate Therapeutics
FATE
|
187 M | $ 1.13 | -5.04 % | $ 134 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Forte Biosciences
FBRX
|
335 M | $ 26.57 | 0.49 % | $ 344 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
169 M | $ 6.14 | -4.36 % | $ 175 M | USA |
|
Foghorn Therapeutics
FHTX
|
356 M | $ 4.74 | -2.87 % | $ 299 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
4.43 B | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fulcrum Therapeutics
FULC
|
539 K | $ 7.55 | -3.58 % | $ 478 K | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 2.25 | -12.3 % | $ 144 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
62.9 B | $ 87.65 | -3.98 % | $ 27.2 B | Germany |
 |
Gilead Sciences
GILD
|
183 B | $ 138.19 | -1.38 % | $ 172 B | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.61 | -3.59 % | $ 189 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
8.08 B | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
1.25 M | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
25 B | $ 27.01 | -2.67 % | $ 17.2 B |  Danmark |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
40.8 B | $ 314.44 | -4.81 % | $ 41.2 B | USA |
 |
Gossamer Bio
GOSS
|
107 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
8.42 B | $ 7.91 | -3.95 % | $ 6.83 B |  Spain |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
GT Biopharma
GTBP
|
2.59 M | $ 0.42 | -6.49 % | $ 2.32 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Halozyme Therapeutics
HALO
|
9.66 B | $ 63.51 | 0.68 % | $ 7.61 B | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 4.42 | -1.34 % | $ 727 M | Britain |